250 researchers will meet from November 16 to 18 at the Baluarte Conference Center at attend for the International Symposium "New Frontiers in the Diagnosis and Treatment of Hematological Tumors", organized by the University of Navarra. The event, in collaboration with the'Institut National de la Santé et la Recherche Medicale' (INSERM), of Toulouse, and the Ramón Areces Foundation, of Madrid, is part of the Spain-France-Andorra Territorial Cooperation Program(POCTEFA).

high school Twenty-five experts from national and international centers, such as Harvard University in Boston, the US National Cancer Institute (NCI) in Bethesda, and Stanford University in California, will present the latest advances in the research and treatment of the most common hematological tumors: leukemias, lymphomas and myelomas. According to Dr. Felipe Prósper and Dr. José A. Martínez Climent, scientists from research center Médica Aplicada (CIMA) and Stanford University in California. Clínica Universidad de Navarra and organizers of the symposium, "the translational research will make it possible to select and apply the most effective drug to each patient according to the cellular and molecular characteristics of their disease".

Among the scientific advances that will be addressed in these conference are new therapeutic strategies carried out through the basic research , as well as the role played by hematopoietic stem cells in the development of hematological tumors . "Highly topical issues such as the identification of the 'Achilles heel' in each lymphoma subject by means of structural and functional genomics programs of study , the personalized use of new molecules and monoclonal antibodies in the treatment of myeloid leukemia and multiple myeloma, or the epigenetic mechanisms involved in the genesis and therapeutic response of lymphoblastic leukemia will also be discussed."

Thanks to funding from European funds and the Government of Navarra, CIMA has initiated a line of research for the synthesis of new drugs for patients with acute leukemias. It is also developing a study to launch targeted therapies for lymphomas.

download the Symposium program in PDF.